TCGA-CV-7183-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.410
- ESTROGEN_RESPONSE_EARLY+0.340
- HYPOXIA+0.340
- NOTCH_SIGNALING+0.320
- CHOLESTEROL_HOMEOSTASIS+0.290
- APICAL_JUNCTION+0.280
- OXIDATIVE_PHOSPHORYLATION+0.280
- FATTY_ACID_METABOLISM+0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- WNT_BETA_CATENIN_SIGNALING+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- E2F_TARGETS-0.460
- ALLOGRAFT_REJECTION-0.410
- INTERFERON_GAMMA_RESPONSE-0.410
- G2M_CHECKPOINT-0.320
- INFLAMMATORY_RESPONSE-0.320
- TNFA_SIGNALING_VIA_NFKB-0.300
- IL6_JAK_STAT3_SIGNALING-0.260
- SPERMATOGENESIS-0.180
- DNA_REPAIR-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0EM-01A-11R-A034-07 | — | B | 0.883 |
| 2 | TCGA-CV-6935-01A-11R-1915-07 | — | — | 0.876 |
| 3 | TCGA-44-7671-01A-11R-2066-07 | — | cohortA2 | 0.815 |
| 4 | TCGA-AN-A0XO-01A-11R-A109-07 | — | C | 0.763 |
| 5 | SRR1313124 | — | B | 0.756 |
| 6 | 20060030.TNBC | — | F | 0.754 |
| 7 | SRR8518245 | — | F | 0.754 |
| 8 | 0177d00d-7d3f-43c8-8d0f-e6333e73efa4 | — | — | 0.753 |
| 9 | SRR6013578 | — | cohortA2 | 0.748 |
| 10 | SRR8613741 | — | F | 0.748 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |